United States: FDA Sets the Stage for Cures Act Breakthrough Devices Program in Highly Anticipated Guidance Document

On October 25, 2017, FDA released a critical draft guidance on the breakthrough medical device pathway established by the 21st Century Cures Act (the "Cures Act"). The Draft Guidance For Industry, Breakthrough Device Pathway ("Draft Guidance") reflects FDA's proposal regarding the process by which a sponsor may seek a designation as a breakthrough device, assigning a team of staff to review devices designated for expedited development and priority review; and information about the criteria that will be used in evaluating a request for designation (the "Breakthrough Devices Program"). This new Breakthrough Devices Program will supersede the current Expedited Access Pathway ("EAP"), which FDA launched in 2015. It will also supersede FDA's Priority Review Program, which implemented statutory criteria for granting priority review to premarket submissions.

As an initial matter, the Draft Guidance clarifies that FDA will approve Breakthrough Devices subject to a Premarket Approval Application ("PMA"), only if it determines there are reasonable assurances of safety and effectiveness. But it also signals that FDA may accept a greater degree of uncertainty of the benefit-risk profile for Breakthrough Devices so long as that uncertainty is sufficiently balanced by other factors, including the probable benefits for patients to have earlier access to the device and adequate postmarketing controls. Furthermore, sponsors can still look to FDA's "Balancing Premarket and Postmarket Data Collection for Devices Subject to Premarket Approval" for guidance on FDA's policy regarding balancing premarket and postmarket data collection during PMA review.

The Draft Guidance outlines the process a sponsor should follow in order to request designation of a Breakthrough Device. A designation request must be submitted prior to the sponsor's marketing application submission. The request must indicate which marketing application type the sponsor intends to submit, and the rationale for this decision. All designation requests should be submitted as a Q‑Submission following the process outline in FDA's Pre-Submission Guidance. FDA will grant or deny designation requests within 60 calendar days of receipt.

The Draft Guidance emphasizes FDA's intent to provide interactive and timely communication with sponsors during device development and review processes, including assigning staff to be available to address questions by institutional review committees within a reasonable time. FDA will assign an FDA manager to each breakthrough device application, who will in turn assign the most appropriate person within FDA to review the application; and the Draft Guidance assures industry that staff reviewing Breakthrough Device applications will be experienced with "innovative approaches to regulatory science." To meet that goal, FDA review teams will undergo regular training, including team meetings, sponsor engagement, and patient interactions.  Senior management also will remain involved throughout the review process.

Additionally, FDA will take measures to expedite the review of Breakthrough Devices, including assigning priority review status to all Breakthrough Device applications. If more than one such application is submitted in a review cycle, the applications will be reviewed based on a first-in-first-reviewed basis. Furthermore, FDA will expedite review of manufacturing and quality systems during preapproval inspections, and even forgo inspection of certain manufacturing sites prior to approval where appropriate. FDA's decision to inspect a manufacturing site will depend on the date of the site's last inspection, and the results of that inspection.

For sponsors seeking approval of a Breakthrough Device, FDA will offer three options for accelerated discussions:

  • "Sprint" Discussions: To support sponsors needing timely resolution of potentially novel issues, FDA will offer "sprint" discussions. These discussions will occur with a goal of reaching mutual agreement on a specific topic within a set time period (e.g., 45 days). The number and format of these discussions, supporting material needed, and timing, will vary based on the project. Similarly, the topic of the discussions should be focused in one general area (e.g., animal study protocol design). The discussions will end with written feedback from FDA to the sponsor.
  • Early Agreement on Data Development Plan ("DDP"): A sponsor can submit a DDP containing both clinical and nonclinical testing approaches, and describing the balance of premarket (and postmarket, if available) data. A DDP is a high-level document intended to help ensure predicable, efficient, transparent, and timely device assessment and review by outlining data collection expectations for the entire product lifecycle. FDA will review the DDP following the same model as its "sprint" discussion model, with a goal to reach early agreement on the DDP.
  • Clinical Protocol Agreement: Sponsors can seek written agreement from FDA on clinical protocols. FDA will document its agreement with a letter.

A sponsor can choose from any of these three options at any point prior to submitting a marketing application for a device. In addition to these three options for accelerated discussion, FDA and the sponsor can engage in regular status updates to discuss the progress of the project and next steps.

FDA also provided guidance on the criteria it will apply to determine whether a device qualifies as a Breakthrough Device. Its guidance is broken down by the categories created in the Cures Act:

  • Devices Providing for More Effective Treatment: FDA will consider, among other things, whether there is a reasonable expectation that a device could provide for more effective treatment or diagnosis relative to the current standard of care.  A complete set of clinical data will not be required for this assessment. The device can treat a life-threatening condition, which FDA defines as a disease or condition for which the likelihood of death is high, unless the course of the disease is interrupted. Alternatively, such condition must have a substantial impact on day-to-day functioning in order to qualify as irreversibly debilitating.
  • Device Represents Breakthrough Technology: FDA will consider the potential for a device to lead to clinical improvement in the diagnosis, treatment, or cure of a life-threatening or irreversibly debilitating condition.
  • No Approved or Cleared Alternatives Exist: FDA will consider whether there is a drug, biological product, or device that has received FDA marketing authorization for the same indications as the proposed breakthrough device. To qualify as an approved or cleared alternative, the product also must be consistent with the current standard of care. If that standard is not well defined, FDA may consult with experts to determine whether the product is an approved or cleared alternative.
  • Device Offers Significant Advantages over Existing Approved or Cleared Alternatives: FDA will consider whether a device reduces or eliminates the need for hospitalization, improves patient quality of life, facilitates the ability of patients to manage their own care, or establishes long-term clinical efficiencies when compared against an existing approved or cleared alternative. One example provided by FDA is an in vitro diagnostic product for earlier diagnosis of preeclampsia.
  • Device Availability Is in the Best Interests of Patients: FDA also will consider the extent to which the device and its proposed indications for use provide another type of specific public health benefit; provide a benefit to patients who are unable to tolerate or are not responding to available therapy; and/or address an unanticipated serious failure in a critical component of an approved device, when alternative treatment would present substantial risk of morbidity to the patient.

FDA has solicited comments on its Draft Guidance, which can be submitted within 60 days of its publication of the Draft Guidance, or by December 24, 2017.  An analysis of the key provisions in the Cures Act related to drug, device, and biologic development and approval can be found in Reed Smith's Client Alert, 21st Century Cures Act.

This article is presented for informational purposes only and is not intended to constitute legal advice.

To print this article, all you need is to be registered on Mondaq.com.

Click to Login as an existing user or Register so you can print this article.

Similar Articles
Relevancy Powered by MondaqAI
Finnegan, Henderson, Farabow, Garrett & Dunner, LLP
In association with
Related Topics
Similar Articles
Relevancy Powered by MondaqAI
Finnegan, Henderson, Farabow, Garrett & Dunner, LLP
Related Articles
Related Video
Up-coming Events Search
Font Size:
Mondaq on Twitter
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
Email Address
Company Name
Confirm Password
Mondaq Topics -- Select your Interests
 Law Performance
 Law Practice
 Media & IT
 Real Estate
 Wealth Mgt
Asia Pacific
European Union
Latin America
Middle East
United States
Worldwide Updates
Registration (you must scroll down to set your data preferences)

Mondaq Ltd requires you to register and provide information that personally identifies you, including your content preferences, for three primary purposes (full details of Mondaq’s use of your personal data can be found in our Privacy and Cookies Notice):

  • To allow you to personalize the Mondaq websites you are visiting to show content ("Content") relevant to your interests.
  • To enable features such as password reminder, news alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our content providers ("Contributors") who contribute Content for free for your use.

Mondaq hopes that our registered users will support us in maintaining our free to view business model by consenting to our use of your personal data as described below.

Mondaq has a "free to view" business model. Our services are paid for by Contributors in exchange for Mondaq providing them with access to information about who accesses their content. Once personal data is transferred to our Contributors they become a data controller of this personal data. They use it to measure the response that their articles are receiving, as a form of market research. They may also use it to provide Mondaq users with information about their products and services.

Details of each Contributor to which your personal data will be transferred is clearly stated within the Content that you access. For full details of how this Contributor will use your personal data, you should review the Contributor’s own Privacy Notice.

Please indicate your preference below:

Yes, I am happy to support Mondaq in maintaining its free to view business model by agreeing to allow Mondaq to share my personal data with Contributors whose Content I access
No, I do not want Mondaq to share my personal data with Contributors

Also please let us know whether you are happy to receive communications promoting products and services offered by Mondaq:

Yes, I am happy to received promotional communications from Mondaq
No, please do not send me promotional communications from Mondaq
Terms & Conditions

Mondaq.com (the Website) is owned and managed by Mondaq Ltd (Mondaq). Mondaq grants you a non-exclusive, revocable licence to access the Website and associated services, such as the Mondaq News Alerts (Services), subject to and in consideration of your compliance with the following terms and conditions of use (Terms). Your use of the Website and/or Services constitutes your agreement to the Terms. Mondaq may terminate your use of the Website and Services if you are in breach of these Terms or if Mondaq decides to terminate the licence granted hereunder for any reason whatsoever.

Use of www.mondaq.com

To Use Mondaq.com you must be: eighteen (18) years old or over; legally capable of entering into binding contracts; and not in any way prohibited by the applicable law to enter into these Terms in the jurisdiction which you are currently located.

You may use the Website as an unregistered user, however, you are required to register as a user if you wish to read the full text of the Content or to receive the Services.

You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these Terms or with the prior written consent of Mondaq. You may not use electronic or other means to extract details or information from the Content. Nor shall you extract information about users or Contributors in order to offer them any services or products.

In your use of the Website and/or Services you shall: comply with all applicable laws, regulations, directives and legislations which apply to your Use of the Website and/or Services in whatever country you are physically located including without limitation any and all consumer law, export control laws and regulations; provide to us true, correct and accurate information and promptly inform us in the event that any information that you have provided to us changes or becomes inaccurate; notify Mondaq immediately of any circumstances where you have reason to believe that any Intellectual Property Rights or any other rights of any third party may have been infringed; co-operate with reasonable security or other checks or requests for information made by Mondaq from time to time; and at all times be fully liable for the breach of any of these Terms by a third party using your login details to access the Website and/or Services

however, you shall not: do anything likely to impair, interfere with or damage or cause harm or distress to any persons, or the network; do anything that will infringe any Intellectual Property Rights or other rights of Mondaq or any third party; or use the Website, Services and/or Content otherwise than in accordance with these Terms; use any trade marks or service marks of Mondaq or the Contributors, or do anything which may be seen to take unfair advantage of the reputation and goodwill of Mondaq or the Contributors, or the Website, Services and/or Content.

Mondaq reserves the right, in its sole discretion, to take any action that it deems necessary and appropriate in the event it considers that there is a breach or threatened breach of the Terms.

Mondaq’s Rights and Obligations

Unless otherwise expressly set out to the contrary, nothing in these Terms shall serve to transfer from Mondaq to you, any Intellectual Property Rights owned by and/or licensed to Mondaq and all rights, title and interest in and to such Intellectual Property Rights will remain exclusively with Mondaq and/or its licensors.

Mondaq shall use its reasonable endeavours to make the Website and Services available to you at all times, but we cannot guarantee an uninterrupted and fault free service.

Mondaq reserves the right to make changes to the services and/or the Website or part thereof, from time to time, and we may add, remove, modify and/or vary any elements of features and functionalities of the Website or the services.

Mondaq also reserves the right from time to time to monitor your Use of the Website and/or services.


The Content is general information only. It is not intended to constitute legal advice or seek to be the complete and comprehensive statement of the law, nor is it intended to address your specific requirements or provide advice on which reliance should be placed. Mondaq and/or its Contributors and other suppliers make no representations about the suitability of the information contained in the Content for any purpose. All Content provided "as is" without warranty of any kind. Mondaq and/or its Contributors and other suppliers hereby exclude and disclaim all representations, warranties or guarantees with regard to the Content, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. To the maximum extent permitted by law, Mondaq expressly excludes all representations, warranties, obligations, and liabilities arising out of or in connection with all Content. In no event shall Mondaq and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use of the Content or performance of Mondaq’s Services.


Mondaq may alter or amend these Terms by amending them on the Website. By continuing to Use the Services and/or the Website after such amendment, you will be deemed to have accepted any amendment to these Terms.

These Terms shall be governed by and construed in accordance with the laws of England and Wales and you irrevocably submit to the exclusive jurisdiction of the courts of England and Wales to settle any dispute which may arise out of or in connection with these Terms. If you live outside the United Kingdom, English law shall apply only to the extent that English law shall not deprive you of any legal protection accorded in accordance with the law of the place where you are habitually resident ("Local Law"). In the event English law deprives you of any legal protection which is accorded to you under Local Law, then these terms shall be governed by Local Law and any dispute or claim arising out of or in connection with these Terms shall be subject to the non-exclusive jurisdiction of the courts where you are habitually resident.

You may print and keep a copy of these Terms, which form the entire agreement between you and Mondaq and supersede any other communications or advertising in respect of the Service and/or the Website.

No delay in exercising or non-exercise by you and/or Mondaq of any of its rights under or in connection with these Terms shall operate as a waiver or release of each of your or Mondaq’s right. Rather, any such waiver or release must be specifically granted in writing signed by the party granting it.

If any part of these Terms is held unenforceable, that part shall be enforced to the maximum extent permissible so as to give effect to the intent of the parties, and the Terms shall continue in full force and effect.

Mondaq shall not incur any liability to you on account of any loss or damage resulting from any delay or failure to perform all or any part of these Terms if such delay or failure is caused, in whole or in part, by events, occurrences, or causes beyond the control of Mondaq. Such events, occurrences or causes will include, without limitation, acts of God, strikes, lockouts, server and network failure, riots, acts of war, earthquakes, fire and explosions.

By clicking Register you state you have read and agree to our Terms and Conditions